Sign in
TMBR Stock Price, Chart, Stats & News
Timber Pharmaceuticals, Inc.
Save
Timber Pharmaceuticals, Inc. (TMBR) does not currently pay a dividend.
1.18M
Market cap
–
Current P/E
–
Forward P/E
TMBR chart
1M
3M
1Y
5Y
Loading chart...
Fundamentals
Gross margin | -15892.35% |
Operating margin | -23125.86% |
Pretax margin | -23289.91% |
Net margin | -23299.05% |
Effective tax rate | -0.04% |
ROA | -188.59% |
ROE | -209.49% |
D/E | 0.06x |
Interest coverage ratio | -84.20x |
TMBR valuation
P/E | – |
P/S | 14.14x |
P/B | 0.14x |
P/CF | -0.05x |
P/FCF | -0.07x |
P/OCF | -0.05x |
PEG | -0.00x |
EV multiple | -0.52x |
About
Timber Pharmaceuticals, Inc. operates as a clinical-stage biopharmaceutical company, specializing in the research, development, and market introduction of treatments for rare dermatological conditions. The company's key product candidates include: TMB-001, a patented topical isotretinoin formulation, which has successfully completed Phase 2b clinical trials. It is designed to address moderate to severe forms of Congenital Ichthyosis (CI), a group of uncommon genetic disorders affecting skin keratinization.
Similar securities
Based on sector and market capitalization
Report issue